Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset-Reference-Cited by-同舟云学术

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Published:2014-12 Issue:12 Volume:25 Page:2378-2385
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Blons H.,Emile J.F.,Le Malicot K.,Julié C.,Zaanan A.,Tabernero J.,Mini E.,Folprecht G.,Van Laethem J.L.,Thaler J.,Bridgewater J.,Nørgård-Petersen L.,Van Cutsem E.,Lepage C.,Zawadi M.A.,Salazar R.,Laurent-Puig P.,Taieb J.

Funder

Fédération Francophone de Cancérologie Digestive

Merck KGaA and Sanofi-Aventis

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/12/2378/16703133/mdu464.pdf

Reference29 articles.

1. ABC of colorectal cancer: epidemiology;Boyle;BMJ,2000

2. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

3. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;Andre;J Clin Oncol,2009

4. K-ras mutations and benefit from cetuximab in advanced colorectal cancer;Karapetis;N Engl J Med,2008

5. Genetic alterations during colorectal-tumor development;Vogelstein;N Engl J Med,1988

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts;European Journal of Cancer;2024-07

2. Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer: a population-wide cohort study;ESMO Gastrointestinal Oncology;2024-06

3. KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer;JAMA Network Open;2023-11-30

4. Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum;Cancer Epidemiology, Biomarkers & Prevention;2023-11-09

5. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials;Annals of Oncology;2023-11